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Predicting HIV Pre-exposure 
Prophylaxis Efficacy for Women 
using a Preclinical Pharmacokinetic-
Pharmacodynamic In Vivo Model
Angela Wahl1, Phong T. Ho1, Paul W. Denton1,*,†,‡, Katy L. Garrett2,*, Michael G. Hudgens3, 
Glenn Swartz4, Cynthia O’Neill4, Fulvia Veronese5, Angela D. Kashuba2 & J. Victor Garcia1
The efficacy of HIV pre-exposure prophylaxis (PrEP) relies on adherence and may also depend on the 
route of HIV acquisition. Clinical studies of systemic tenofovir disoproxil fumarate (TDF) PrEP revealed 
reduced efficacy in women compared to men with similar degrees of adherence. To select the most 
effective PrEP strategies, preclinical studies are critically needed to establish correlations between 
drug concentrations (pharmacokinetics [PK]) and protective efficacy (pharmacodynamics [PD]). We 
utilized an in vivo preclinical model to perform a PK-PD analysis of systemic TDF PrEP for vaginal 
HIV acquisition. TDF PrEP prevented vaginal HIV acquisition in a dose-dependent manner. PK-PD 
modeling of tenofovir (TFV) in plasma, female reproductive tract tissue, cervicovaginal lavage fluid and 
its intracellular metabolite (TFV diphosphate) revealed that TDF PrEP efficacy was best described by 
plasma TFV levels. When administered at 50 mg/kg, TDF achieved plasma TFV concentrations (370 ng/ml)  
that closely mimicked those observed in humans and demonstrated the same risk reduction (70%) 
previously attained in women with high adherence. This PK-PD model mimics the human condition 
and can be applied to other PrEP approaches and routes of HIV acquisition, accelerating clinical 
implementation of the most efficacious PrEP strategies.
In 2012, Truvada® , a fixed-dose combination tablet consisting of two nucleoside reverse transcriptase inhibitors 
(NRTIs), tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC), received FDA approval to be used as 
pre-exposure prophylaxis (PrEP) for HIV prevention in high-risk individuals. Truvada® received this licensing 
on the basis of a 44–75% decrease in HIV incidence in clinical trials of serodiscordant heterosexual couples 
(Partners PrEP) and men who have sex with men (MSM) (iPrEX)1,2.
Two large Phase III HIV prevention trials conducted in women, FEM-PrEP and VOICE, failed to show HIV 
prevention efficacy for TDF taken with or without FTC3,4, whereas women in a third clinical trial, Partners PrEP, 
had a high degree of protection2. These results were attributed to differing rates of adherence in the studies. 
However, the degree of adherence needed to effectively prevent HIV infection may be dependent on the route of 
acquisition as evidenced by recent data from the iPrEX clinical trial demonstrating that two doses of Truvada® 
per week were sufficient to reduce rectal HIV acquisition in MSM5. This same level of adherence failed to protect 
women against vaginal HIV acquisition in FEM-PrEP and VOICE3,4.
Together, these clinical trial data indicate the importance of understanding the relationship between drug 
concentrations at sites of HIV acquisition (pharmacokinetics [PK]) and efficacy (pharmacodymamics [PD]) in 
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men and women for different PrEP regimens. Understanding antiretroviral (ARV) concentrations in various flu-
ids and tissues relevant to HIV acquisition after clinical dosing has occasionally been included in early prevention 
product trials, but typically has progressed in parallel with larger efficacy studies. Mostly, it is addressed only as a 
follow-up analysis of samples collected from these studies, and in many instances, only plasma drug concentra-
tions were measured. Although this limited PK analysis can be useful in understanding post trial outcomes, the 
field needs improved pre-Phase III methods to better inform effective trial design and more accurately predict 
outcomes.
This need was identified by the HIV Prevention Pharmacology Best Practices Working Group (BPWG), sup-
ported by the Division of AIDS (DAIDS) at the National Institute of Allergy and Infectious Disease (NIAID) 
and the Bill and Melinda Gates Foundation (BMGF). In particular, dose ranging evaluations in animal models 
were identified as critical to determining whether predictive or relational PK-PD models could be established to 
inform dose selection in human studies6.
In bone marrow/liver/thymus (BLT) humanized mice, the female reproductive tract (FRT) and gastrointes-
tinal tract are reconstituted with human immune cells which can then be infected with HIV7–18. BLT mice have 
been extensively utilized as an in vivo preclinical animal model to explore the efficacy of systemic and topi-
cal ARV strategies to prevent vaginal HIV acquisition7–11,14. Approaches have included topical tenofovir (TFV) 
and systemic TDF administered in combination with FTC8,9. However, BLT mice are bioengineered individually 
and the in situ development of a human immune system in each animal occurs over a period of several weeks. 
Comparatively, other related “off the shelf ” strains like BALB/c mice are more readily available and less costly, 
making them appealing to use in preclinical models. BALB/c mice, however, lack human immune cells and thus 
are not susceptible to HIV infection. In order to use BALB/c mice and maximize resource allocation, a discerna-
ble dose-exposure relationship between BLT and BALB/c mice is needed. Therefore, we designed an investigation 
to understand the PK-PD relationship of systemically administered TDF in protecting BLT mice against a vaginal 
HIV challenge.
We determined concentrations (PK) of TFV and its active intracellular metabolite (TFV diphosphate 
[TFVdp]) in BLT and BALB/c mice, and established the degree of protection (PD) in BLT mice. TDF PrEP pre-
vented vaginal HIV acquisition in a dose-dependent manner in BLT mice. PK-PD modeling of TFV in plasma, 
FRT tissue, cervicovaginal lavage (CVL) fluid and TFVdp in FRT tissue revealed that TDF PrEP efficacy was best 
described by plasma TFV levels. When administered at 50 mg/kg, TDF achieved plasma TFV concentrations 
similar to those observed in humans and demonstrated the same risk reduction (~70%) attained in women with 
high adherence in Partners PrEP19.
Results
Dose dependence of TDF PrEP activity during vaginal HIV challenge in BLT humanized mice. 
TDF (20, 50, 140, or 300 mg/kg) was administered to BLT mice systemically once daily for seven consecutive days. 
BLT mice were exposed vaginally to HIV 3 h after the third TDF dose (Fig. 1a) and then received four additional 
daily doses of TDF to reproduce current clinical trials of systemic HIV PrEP in which study participants receive 
daily ARVs until testing positive for HIV. As a positive control for vaginal HIV acquisition, untreated (no TDF 
administered) BLT mice were exposed once vaginally to HIV. Following HIV exposure, peripheral blood plasma 
HIV-RNA levels in BLT mice were monitored longitudinally with a real-time PCR viral load assay. At necropsy, 
the presence of HIV-DNA in peripheral blood and tissues was determined with real-time PCR. Protection was 
defined as the absence of detectable HIV-RNA in plasma at all time points analyzed and the absence of detectable 
HIV-DNA in peripheral blood and tissues at necropsy.
In the absence of TDF treatment, HIV-RNA was readily detected in the plasma of 75% (21/28) of control 
animals exposed vaginally to HIV (Fig. 1b and Table 1). Plasma HIV-RNA was detected in the vast majority 
of HIV-infected BLT mice by two weeks post-exposure (19/21) and in all HIV-infected mice by 4 weeks 
post-exposure (Fig. 1b). HIV-RNA was detected in the plasma of only 50% (7/14), 33% (4/12), and 15% (2/13) 
of BLT mice administered 20, 50, and 140 mg/kg TDF, respectively (Fig. 1c–f and Table S1). No HIV-RNA was 
detected in the plasma of any animal that received 300 mg/kg TDF at all time points analyzed up to 6 weeks 
post-exposure (Fig. 1f and Table S1). HIV transmission was significantly reduced in BLT mice administered 
50 mg/kg (p = 0.02), 140 mg/kg (p = 0.0006), or 300 mg/kg (p < 0.0001) TDF (Fig. 1c–g and Table 1). Thus the 
risk reduction in HIV acquisition increased as the systemic dose of TDF increased (Table 1). The majority (8/13) 
of BLT mice which acquired HIV despite TDF administration had detectable HIV-RNA in their plasma by two 
weeks post-exposure.
The absence of HIV infection in BLT mice without detectable HIV-RNA in plasma was confirmed at nec-
ropsy by determining the presence of HIV-DNA in peripheral blood and tissues of BLT mice with real-time PCR 
(Table S1). No HIV-DNA was detected in peripheral blood or tissues analyzed from BLT mice with undetectable 
levels of HIV-RNA in plasma confirming protection from infection. In contrast, HIV-DNA was readily detected 
in peripheral blood and tissues analyzed from HIV-infected BLT mice that received TDF and had detectable 
HIV-RNA.
Comparative TFV and TFVdp concentrations in BLT and BALB/c mice. BALB/c mice are more readily 
available and less costly than BLT mice, and the immune deficient mouse strains utilized to generate them, but 
they lack human immune cells and thus are not susceptible to HIV infection. To determine if BALB/c mice could 
be established as a surrogate in vivo model for PK analysis, TFV concentrations in plasma, CVL, and FRT tissue 
and TFVdp concentrations in FRT tissue 24 h following a single 300 mg/kg dose of TDF to BALB/c (n = 8) and 
BLT (n = 8) mice were determined (Fig. 2a and Tables S2 and S3). No significant difference was observed in 
(median [min-max]) plasma TFV concentrations between BALB/c (409 [328–584] ng/ml) and BLT (376 [41.5–
705] ng/ml) mice (p = 0.43) (Fig. 2b and Table S2), with median concentrations differing by < 9%. CVL TFV 
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concentrations were significantly higher (p = 0.007) in BALB/c mice (1,725 [25.2–5120] ng/ml) compared to that 
of BLT mice (23.8 [8.7–1830] ng/ml) (Fig. 2c and Table S2). Median concentrations differed by ~200%. Although 
there was no significant difference in the concentration of TFV in the FRT tissue of BALB/c (6,005 [4,982–
10,267] ng/g) and BLT (4,705 [923–15,680] ng/g) mice (p = 0.23) (Fig. 2d and Table S2) or in the concentration 
Figure 1. In vivo efficacy of systemic TDF PrEP for vaginal HIV acquisition. (a) The efficacy of systemic 
TDF PrEP was evaluated in BLT humanized mice. BLT mice were administered TDF systemically once daily for 
7 consecutive days and challenged vaginally with HIV-1JR-CSF 3 h after the third TDF dose. Following exposure, 
HIV-RNA levels were monitored longitudinally in peripheral blood plasma. BLT mice with detectable levels 
of plasma HIV-RNA are shown in red and mice with no detectable HIV-RNA in plasma are shown in black. In 
panels B-F HIV-RNA levels in plasma are shown for (b) control (no TDF treatment) BLT mice (n = 28) and BLT 
mice dosed with (c) 20 mg/kg (n = 14), (d) 50 mg/kg (n = 12), (e) 140 mg/kg (n = 13), and (f) 300 mg/kg (n = 11) 
TDF. The assay limit of detection (750 HIV-RNA copies/ml) is shown with a dashed line (b–f). (g) A Kaplan 
Meier plot depicts the percent of HIV-negative mice in each TDF PrEP group. A log-rank Mantel-Cox test was 
used to compare the percent of HIV-negative mice between groups of control mice and mice that received TDF 











(95% CI), % P
20 mg/kg 14 7 7 61% (− 1.2 to 85) 0.05
50 mg/kg 12 4 8 70% (16 to 89) 0.02
140 mg/kg 13 2 11 83% (53 to 94) 0.0006
300 mg/kg 11 0 11 88% (66 to 95) < 0.0001
Control 28 21 7 NA NA
Table 1.  Protective Efficacy of TDF PrEP. Risk reduction: (1-Hazard Ratio) × 100. NA: not applicable.
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of TFVdp in BALB/c (3,000,089 [907,308–5,219,985] fmol/g) and BLT (1,870,182 [35,336–3,023,969] fmol/g) 
mice (p = 0.10) (Fig. 2e and Table S2), the median concentrations for TFV and TFVdp in the FRT tissue differed 
by 24% and 46% in BLT mice compared to BALB/c mice, respectively. Therefore, the conversion factor calculated 
(by dividing median concentrations) to modify the concentrations in BALB/c mice to BLT mouse exposure in the 
FRT tissue was 0.78 for TFV and 0.62 for TFVdp. A CVL conversion factor was not generated due to large (and 
expected) variability in sample concentrations.
PK assessment of tenofovir in BALB/c mice. After determining the relationship between drug con-
centrations in BALB/c and BLT mice, the PK of TFV in BALB/c mice systemically administered daily doses of 
20, 50, 140, or 300 mg/kg TDF was evaluated (Fig. 3a). Molar conversion of TFVdp in FRT tissue was also calcu-
lated (fmol/g TFVdp ÷ fmol/g TFV). Significantly higher concentrations of TFV were detected in the plasma, 
CVL, and FRT tissue of mice dosed with 140–300 mg/kg TDF (Fig. 3b–d and Table S4) compared to those dosed 
with 20–50 mg/kg. The concentration of TFVdp in FRT tissue was also significantly higher in mice dosed with 
140–300 mg/kg TDF compared to mice dosed with 20–50 mg/kg. However, the concentrations did not increase 
linearly with increasing dose across all matrices. Dose proportionality was declared for TFV plasma concentra-
tions (Fig. 4a), since the slope (90% CI) of the linear regression model was 1.03 (0.86, 1.20) (Fig. 4a). However, 
concentrations of TFV and TFVdp in FRT tissue were not dose proportional (slope [90% CI]), TFV (0.86 [0.59, 
1.12]) and TFVdp (0.86 [0.57, 1.15)]). TFV concentrations in CVL was also not dose proportional (1.33 [0.45, 
2.21]). Variability in drug concentrations are reported as percent coefficient of variation (CV%). Plasma TFV, FRT 
Figure 2. Pharmacokinetics of TFV in BALB/c and BLT mice. (a) BALB/c (n = 8) and BLT (n = 8) mice were 
administered a single dose of 300 mg/kg TDF and the concentrations of TFV (plasma, CVL, and the FRT) and 
TFVdp (FRT) measured 24 h later. The concentration of TFV present in (b) plasma, (c) CVL, and (d) the FRT 
of BALB/c and BLT mice. (e) The concentration of TFVdp in the FRT of BALB/c and BLT mice. (b–e) Shown 
are the median TFV and TFVdp concentrations (horizontal line) and interquartile range (vertical lines). An 
exact Mann-Whitney test was used to compare the concentrations of TFV and TFVdp between BALB/c and 
BLT mice (*p < 0.05, **p < 0.01). Mouse vector art authored by Gwilz (https://commons.wikimedia.org/wiki/
File%3AVector_diagram_of_laboratory_mouse_(black_and_white).svg).
www.nature.com/scientificreports/
5Scientific RepoRts | 7:41098 | DOI: 10.1038/srep41098
TFV, and FRT TFVdp all had a CV% of approximately 100%. The mean (standard deviation) of TFVdp conversion 
in tissue was 13.1 (7.4)%.
PK-PD analysis of tenofovir. The in vivo protective efficacy of TDF in BLT mice (Fig. 1) was correlated to 
the corresponding concentrations of TFV and/or TFVdp measured in plasma, FRT tissue, and CVL of BALB/c 
mice using the same TDF doses (Fig. 3). Final estimated parameters of the PD models, along with precision 
estimates (SE) are shown in Table 2. Precision was highest in the dose-response model (Fig. 4b) and lowest in the 
CVL concentration model (Table 2), coinciding with inter-individual variability in concentrations. The efficacy 
predicted for 140 and 300 mg/kg TDF doses were 86 and 93% (Fig. 4b), respectively, compared to the 84 and 
100% observed, demonstrating good model fit. Estimated effect curves for plasma and tissue concentrations 
are shown in Fig. 4c. The median plasma TFV concentrations in the 20, 50, 140, and 300 mg/kg TDF dosing 
cohorts were predicted to provide 58, 67, 84, and 88% protection, respectively (Fig. 4c). Predicted efficacy based 
on median TFV concentrations was within 10%, again demonstrating good model fit. For TFVdp, median con-
centrations were highest in the 140 mg/kg cohort, resulting in no predicted increase in efficacy in animals dosed 
with 300 mg/kg TDF (Fig. 4c). Although the standard errors for all estimated parameters in tissue was < 23%, 
Figure 3. Pharmacokinetics of TFV in peripheral blood plasma, CVL and the FRT. (a) BALB/c mice were 
administered TDF once daily for three days and the concentrations of TFV (plasma, CVL, and FRT) and 
TFV-DP (FRT) measured 3 h after the third TDF dose in order to determine the concentrations of TFV and 
TFVdp present systemically and locally at the time of vaginal HIV challenge in our study. TFV concentration 
in (b) plasma, (c) CVL, and (d) the FRT of BALB/c mice dosed with 20 mg/kg (n = 8), 50 mg/kg (n = 8), 140 mg/kg 
(n = 8), and 300 mg/kg (n = 8) TDF. (e) TFVdp concentration in the FRT of BALB/c mice dosed with 20 mg/kg 
(n = 8), 50 mg/kg (n = 8), 140 mg/kg (n = 8), and 300 mg/kg (n = 8) TDF. (b–e) Shown are the median TFV and 
TFVdp concentrations (horizontal line) and interquartile range (vertical lines). Dashed lines represent the 95% 
confidence interval. An exact Wilcoxon rank sum test with Bonferroni correction for multiple comparisons was 
used to compare the concentrations of TFV and TFVdp between mice dosed with 20 mg/kg, 50 mg/kg, 140 mg/kg, 
and 300 mg/kg TDF (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). Mouse vector art authored by Gwilz 
(https://commons.wikimedia.org/wiki/File%3AVector_digram_of_laboratory_mouse_(black_and_white).svg).
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Figure 4. PK-PD modeling of systemic TDF PrEP. (a) Log tenofovir (TFV) plasma concentration to dose. 
Individual concentrations are displayed as open circles and the regression line is in red. (b) PD effect by dose. 
Curve estimating fraction of protection conferred by increasing dose. Observed data points are overlaid as 
closed circles. Fraction protected is on the y-axis with dose (mg/kg) on the x-axis. Dashed lines represent the 
95% confidence interval. (c) PD effect by concentration curves estimating fraction of protection conferred by 
concentrations of TFV in plasma and the FRT as well as TFVdp in the FRT. Observed data (median [range]) 
are overlaid symbols with error bars. FRT TFV concentrations are scaled by 0.78 and TFVdp concentrations are 
scaled by 0.62. Values are offset along the y-axis for visual purposes. Fraction protected is along the y-axis and 
concentrations are on the x-axes.
Parameter Dose (mg/kg) Plasma (ng/ml) FRT TFV (ng/g) FRT TFVdp (fmol/g) CVL (ng/ml)
E0 0.2502 [3.67] 0.2580 [13.24] 0.3151 [7.299] 0.2622 [7.405] 0.4016 [8.918]
EC50 38.7 [7.628] 259 [19.6] 4101 [21.18] 6.052e5 [22.75] 238.7 [51.53]
H 1.138 [10.4] 0.7449 [14.98] NA NA NA
Table 2.  PD Model Parameters. All values are presented as mean (standard error [SE]). E0: baseline effect, 
EC50: concentration or dose reflecting half-maximal effect, H: Hill’s coefficient, FRT: female reproductive tract, 
TFV: tenofovir, TFVdp: tenofovir diphosphate, CVL: cervicovaginal lavage, and NA: not applicable.
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there was considerable overlap in the concentrations providing 84–100% protection, since TFV and TFVdp con-
centrations in FRT tissue did not increase linearly with dose (Fig. 4c).
Discussion
Worldwide, HIV/AIDS is the leading cause of death in young women20,21, making HIV prevention a critical 
component to their survival. In the absence of a vaccine or the elimination of high-risk behaviors, PrEP provides 
a viable alternative to prevent HIV acquisition. TDF, with or without FTC, showed promising efficacy in early, 
preclinical studies22,23. However, clinical trial results were mixed.
Three studies (Partners PrEP, VOICE, and FemPrEP), using the same daily HIV treatment dose of TDF, but 
enrolling different populations of HIV-uninfected women, yielded conflicting results1,3,4. Partners PrEP enrolled 
older women in a long-term serodiscordant relationship and demonstrated that TDF was 71% effective in pro-
tecting against HIV acquisition. VOICE and FemPrEP enrolled younger women, most of whom were without 
a steady partner, and demonstrated that TDF was not effective in protecting women from HIV infection. This 
difference in efficacy was largely attributed to adherence, since the protected women in Partners PrEP had double 
the rate of TFV detected in plasma compared to women enrolled in the VOICE and FemPrEP studies, and low 
rates of TFV detection were seen in the seroconverters in each study1,3,4.
The determination of PK-PD relationships is a fundamental component of drug development. Given the 
inconsistent outcomes in phase II PrEP studies, there is increased need to appropriately study PK-PD relation-
ships with prevention products in order to inform development decisions. The HIV Prevention Pharmacology 
BPWG determined that one of the most critical needs in the HIV prevention field is to delineate the PK relation-
ship between humans and animal models of HIV infection6. A number of key studies were identified that could 
potentially address this specific need. One of these is our investigation into the PK-PD relationship of TDF in BLT 
mice, a previously validated in vivo preclinical model of vaginal HIV acquisition7–10,12–14,24. We chose TDF due to 
its widespread clinical use and the unique pharmacological challenges the active intracellular metabolite provides 
to PK-PD modeling.
Our results demonstrated that the degree of protection conferred by daily systemic TDF in BLT mice was 
dose-dependent. Vaginal HIV acquisition was significantly decreased in mice receiving 50 and 140 mg/kg TDF 
and completely prevented in mice administered 300 mg/kg TDF. The PD model of dose and efficacy consist-
ently predicted higher protective effects with increasing TDF doses, with parameter standard errors ≤ 10%. These 
results were paralleled by a dose proportional increase in TFV plasma concentrations and predictive efficacy sim-
ilar to the dose-response model. Additionally, we saw similar rates of predicted protection based on TFV tissue 
concentrations in mice dosed with 140 and 300 mg/kg, but not those dosed with 20 or 50 mg/kg. Thus, across the 
entire dose range, plasma concentrations provided the best physiological predictor of efficacy.
Our PD models were unable to generate appreciable increases in protection with FRT TFVdp concentrations at 
doses above 140 mg/kg, which we attribute to concentration variability in this tissue. FRT TFVdp concentrations 
in BALB/c and BLT mice were higher than those reported in human and pigtail macaque vaginal tissue tissue 24 h 
after a single systemic dose of FTC/TDF. However, it is important to note that in our study, we measured TFVdp 
levels in the entire FRT (uterus, cervix, and vagina)25,26. TFV concentrations in CVL also increased with higher 
doses of TDF, but not in a dose proportional manner. These data are consistent with human CVL data which are 
known to be more variable (by up to 1 log) than blood plasma25. In women, penetration of TFV into vaginal and 
cervical tissue, and cervicovaginal secretions (CVS) has been demonstrated, as determined by the AUC ratio of 
tissue or fluid to plasma27. TFV levels in human vaginal and cervical tissue are lower than plasma25,28,29. Here, we 
observed higher TFV concentrations in FRT tissue of mice compared to plasma. In directly-aspirated CVS from 
women, TFV concentrations are 25% lower than plasma after multiple-dosing30. TFV CVL concentrations were 
more than 3-fold higher in BALB/c mice compared to plasma. Higher TFV concentrations in vaginal secretions 
compared to plasma has also been reported in pigtail macaques following systemic FTC/TDF administration26. 
However, TFV levels in CVL were significantly lower in BLT mice compared to BALB/c mice. As observed in 
humans, TFV levels were lower in CVL of BLT mice compared to plasma.
All together, we observed a clear trend toward greater protection with higher systemic TDF doses and higher 
TFV plasma concentrations. Plasma TFV concentrations agreed best with protective efficacy of TDF PrEP over 
the dosing range. TFV plasma concentrations most closely mimicking human data were observed in BALB/c mice 
dosed with 50 mg/kg TDF31,32. A 50 mg/kg dose of TDF demonstrated 70% risk reduction in BLT mice which was 
comparable to the 76% risk reduction observed in women in Partner’s PrEP with high adherence to TDF19.
Dose-ranging studies were identified as a critical need by the HIV Prevention BPWG in order to discern 
PK-PD relationships between animal models and humans6. Here, we showed a strong dose-response relationship 
and increasing protection with increasing TFV plasma concentrations across the entire dose range in the BLT 
mouse model of vaginal HIV acquisition. Peripheral blood plasma is a much more readily accessible biological 
matrix to sample and continually monitor in patients compared to tissue and CVS. Of note, we did not evaluate 
the efficacy of TDF PrEP for rectal HIV acquisition or colorectal TFV/TFVdp tissue concentrations, therefore, we 
cannot extrapolate our PK-PD data in this vaginal challenge model to rectal challenge. Colorectal tissue concen-
trations are likely different from genital concentrations, requiring different doses and concentrations to achieve 
protective effects. Although the protective efficacy of systemic TDF PrEP for vaginal HIV acquisition was best 
described by plasma TFV concentrations, the tissue distribution of other PrEP agents will need to be evaluated to 
determine if plasma or tissue drug concentrations are best associated with protective efficacy.
In summary, this preclinical PK-PD model mimics the human condition and provides a framework to accel-
erate clinical implementation of efficacious PrEP strategies by 1) assessing their penetration, distribution, and 
accumulation into relevant sites of HIV exposure, 2) evaluating their protective efficacy for different modes of 
HIV acquisition, 3) determining if plasma or tissue drug concentrations are best associated with predictive effi-
cacy, and 4) identifying the best drug doses and dosing regimens to evaluate in clinical studies.
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Methods
Experimental design. The objective of the study was to investigate the PK-PD relationship of TDF for PrEP 
in a preclinical in vivo BLT humanized mouse model of vaginal HIV acquisition. The PD assessment of TDF PrEP 
for prevention of vaginal HIV acquisition was evaluated by administering BLT mice a single intraperitoneal (IP) 
dose of 20, 50, 140, or 300 mg/kg TDF daily for seven consecutive days and exposing mice vaginally to HIV-1JR-CSF 
3 h after the third TDF dose as illustrated in Fig. 1a. A Kruskal-Wallis test using Dunn’s multiple comparisons 
test was performed to ensure that peripheral blood humanization levels (%hCD4+ T cells of live cells) between 
exposure groups were equivalent. Vaginal HIV exposures were performed as previously described by pipetting 
virus (3.5 × 105 TCIU HIV-1JR-CSF) in vehicle (RPMI medium, 20 μ l total volume) directly into the vaginal cavity 
of anesthetized BLT mice7–14,24. Following HIV exposure, peripheral blood plasma HIV-RNA levels in BLT mice 
were monitored longitudinally and at necropsy, the presence of HIV-DNA in peripheral blood and tissues was 
determined with real-time PCR as described below. Protection was defined as the absence of detectable HIV-RNA 
in peripheral blood plasma at all time points analyzed and the absence of detectable HIV-DNA in peripheral 
blood and tissues at necropsy. For the comparison of drug levels between BALB/c and BLT mice, animals were 
administered a single IP dose of 300 mg/kg TDF and samples collected 24 h later (Fig. 2a). For the PK assessment, 
BALB/c mice were administered a single daily IP dose of 20, 50, 140, or 300 mg/kg TDF for three consecutive days 
and necropsied 3 h after the third TDF dose (Fig. 3a) to mimic fluid and tissue concentrations at the time of HIV 
exposure in BLT mice. The presence of TFV and/or TFVdp was determined in peripheral blood, CVL, and FRT 
tissue collected at necropsy as described below.
Generation of BLT humanized mice. BLT humanized mice were bioengineered as previously descri
bed7–14,16,17,24,33–38. Briefly, human fetal liver and thymus tissue (ABR Inc., Alameda, CA) were implanted under 
the kidney capsule of irradiated (200 rads) female NOD.Cg-Prkdcscid ll2rgtm1Wjl/SzJ mice (NSG; The Jackson 
Laboratory, Bar Harbor, ME). Following tissue implantation, mice received autologous CD34+ hematopoietic 
stem cells via tail vein injection. Human immune cell reconstitution was monitored in the peripheral blood of 
BLT mice longitudinally by flow cytometry as previously described7–14,16,17,24,33–38. BALB/c is the parental strain 
for the immunodeficient mouse strain Cg-Prkdcscid which was crossed with NOD mice to generate NOD.
CB17-Prkdcscid/J mice. The NOD.CB17-Prkdcscid/J strain was then crossed with B6.129S4-Il2rgtm1Wjl/J mice to 
create NSG mice which were used for the preparation of BLT mice39. BLT mice and BALB/c mice (The Jackson 
Laboratory, Bar Harbor, ME) were maintained by the Division of Laboratory Animal Medicine at UNC-Chapel 
Hill according to protocols approved by the Institutional Use and Care Committee and in adherence to the NIH 
Guide for the Care and Use of Laboratory Animals.
Virus. HIV-1JR-CSF, a CCR5-tropic early passage primary isolate was used for these experiments. HIV-1JR-CSF 
has been well characterized for its ability to infect humanized mice after vaginal exposure in multiple studies7–10,12–14,24. 
In addition, it has been extensively used to investigate the in vivo efficacy of HIV prevention approaches 
in humanized mice7–10,14. Concentrated stocks of HIV-1JR-CSF were prepared by transient transfection of 
293 T cells and titered in triplicate on TZM-bl cells (NIH AIDS Research and Reference Reagent Program) 
as previously described to calculate the number of tissue culture infectious units per ml (TCIU)/ml of virus 
preparation7–12,14,16,17,24,33,35–38.
Drug. TDF was obtained through the NIH AIDS Reagent Program, NIAID, NIH and also kindly provided by 
Jim Rooney at Gilead Sciences, Inc (Foster City, CA). TDF was solubilized in physiological saline (Hospira, Lake 
Forest, IL) at a final concentration of 10 mg/ml.
Analysis of HIV infection in BLT mice. Following vaginal HIV exposure, HIV-RNA levels were monitored 
longitudinally in peripheral blood plasma of BLT mice with a real-time PCR viral load assay (limit of detection: 
750 HIV-RNA copies/ml) as previously described7,10–12,14,24,40. The presence of HIV-DNA in tissues and peripheral 
blood cells collected from BLT mice at necropsy was determined by real-time PCR analysis of DNA extracted 
from mononuclear cells as previously described7,10–12,14,24,40. Prior to necropsy, animals were euthanized with an 
overdose of anesthesia followed by cervical dislocation. To control for the presence of amplifiable DNA extracted 
from human cells, the presence of human gamma globulin DNA was confirmed by real-time PCR for all samples. 
Protection from HIV infection was defined by the absence of detectable HIV-RNA in plasma at all time points 
analyzed and the absence of detectable HIV-DNA in peripheral blood cells and tissues at necropsy.
Sample collection and handling. Peripheral blood was collected with EDTA coated capillary tubes and 
plasma was subsequently isolated by centrifugation (2,000 RPM for 5 min at RT). CVL were performed with ster-
ile PBS (3 washes of 20 μ l each, ~60 μ l total volume) as previously described11,12,40. The entire FRT (vagina, cervix 
and uterus) was weighed and snap frozen with liquid nitrogen. All samples were stored at − 80 °C until analysis.
Quantification of TFV and TFVdp. Once TDF is administered, it is metabolized to TFV by hydrolases in 
the gut and plasma. Circulating TFV is subsequently metabolized intracellularly by cellular kinases to its active 
metabolite TFVdp. We quantified TFV and TFVdp in biological matrices using validated LC-MS/MS methods as 
previously described41. Quantification of TFV concentrations in plasma and CVL was performed by protein pre-
cipitation and LC-MS/MS analysis with an isotopically-labeled internal standard (13C TFV). TFV was eluted from 
a Waters Atlantis T3 (100 × 2.1 mm, 3 μ m particle size) analytical column and an API-5000 triple quadrupole 
mass spectrometer (AB Sciex, Foster City, CA) was used to detect the analytes. Data were collected using AB Sciex 
Analyst Chromatography Software (Analyst version 1.6.1). The dynamic range of this assay was 2–2000 ng/mL 
for plasma and 1–2000 ng/mL for CVL using a 1/concentration2 weighted linear regression. For measuring 
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concentrations in mucosal tissues, TFV and TFVdp was extracted from tissue homogenate by protein precip-
itation with isotopically-labeled internal standards (13C TFV and 13C TFVdp). TFV was eluted from a Waters 
Atlantis T3 (100 × 2.1 mm, 3 μ m particle size) analytical column, and TFVdp was eluted from a Thermo Biobasic 
AX (50 × 2.1 mm, 5 μ m particle size) analytical column. An API-5000 triple quadrupole mass spectrometer 
was used to detect all analytes. Data were collected using AB Sciex Analyst Chromatography Software (Analyst 
version 1.6.1). The dynamic range of this assay was 0.3–300 ng/mL of homogenate for each compound using a 
1/concentration2 weighted linear regression. Concentrations were ultimately converted into ng/g (TFV) or fmol/g 
(TFVdp) tissue for final reporting.
PK data analysis. A linear regression was fit (Eqn. 1) for the log-transformed concentration data of TFV and 
TFVdp to log-transformed dose in order to determine if concentrations increased in a dose proportional manner. 
Dose proportionality was declared if the 90% confidence interval for the slope β was contained in the interval 
0.744–1.2642. Regression analyses were performed in RStudio43.
= µ + β + εlog(concentration) log(dose) (1)
Comparison of drug exposure between BLT and BALB/c mice. Concentrations of TFV and/or 
TFVdp in plasma, CVL, and FRT tissue were compared between BLT and BALB/c mice to determine the similar-
ity in TFV and TFVdp exposure. This was done to identify whether any adjustment (or conversion) factor would 
need to be applied to the more frequently collected BALB/c samples to estimate the BLT concentrations when 
establishing the PK-PD relationship for BLT mice. Median concentrations were calculated for each matrix; if the 
medians between BLT and BALB/c mice differed by more than 20% an adjustment (conversion) factor to predict 
BLT concentrations using BALB/c concentrations was generated by dividing the respective median values. If the 
median values differed by less than 20%, no adjustment was made to the concentrations.
PD model development. The concentrations of TFV and TFVdp obtained from the BALB/c mice in the 
PK assessment were related to the in vivo efficacy data from BLT mice in the PD assessment to generate predictive 
PK-PD models for each biological matrix. A fractional sigmoidal Hill function (Eqn. 2) was used to describe the 
proportion of animals protected from vaginal HIV challenge based on the concentration of TFV or TFVdp in 
each of the matrices. The same model was also used to describe the relationship between protection and TDF 
dose (dose-response model). A conversion factor (as described above) was used to adjust BALB/c concentra-
tions to expected BLT concentrations for tissue TFV and TFVdp concentrations. In this model, Emax was the 
maximum protection and E0 was the baseline protection. EC50 was the concentration at which half-maximal 
efficacy occurs and H was the Hill’s coefficient. DV was the dependent variable (i.e, TFV or TFVdp concentra-
tion) being modeled. Parameters were estimated using the maximum likelihood (ML) estimation function in 
ADAPT5 (Biomedical Simulations Resource, Los Angeles, CA, USA). Emax was fixed to one for all models. H was 
fixed to one for TFV in tissue and CVL because the estimation routine resulted in false minima (H < 0.5). H was 
estimated in all other matrices. Proportional residual error variance models were used and estimated, with CV% 
of the assays as initial estimates.
= + − +⁎E E [(Emax E ) DV ]/(EC DV ) (2)0 0 H 50 H H
Statistical analysis. Statistical analyses were performed in Prism, version 6 (Graph Pad, La Jolla, CA). 
Two-sided testing and an alpha of 0.05 was used. A log-rank Mantel-Cox test was used to compare the per-
cent of HIV-negative BLT mice between groups of control mice and mice that received TDF PrEP. An exact 
Mann-Whitney U test was used to compare TFV and TVFdp concentrations between BALB/c and BLT mice. 
TFV and TVFdp concentrations between BALB/c mice dosed with 20, 50, 140, or 300 mg/kg TDF were compared 
with an exact Wilcoxon rank sum test using the Bonferroni correction for multiple comparisons.
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